Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hasibur Rehman

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
International Journal of Physiology, Pathophysiology and Pharmacology|May 18, 2016
The mitochondria-targeted antioxidant MitoQ attenuates liver fibrosis in miceHasibur Rehman, Qinlong Liu, Yasodha Krishnasamy, et al.
Molecular Neurodegeneration|June 23, 2025
The PKCι-β-arrestin2 axis disrupts SORLA retrograde trafficking, driving its degradation and amyloid pathology in Alzheimer's diseaseHasibur Rehman, Shun Yan, Shalini Saggu, et al.
JCI Insight|July 19, 2022
ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitorsHasibur Rehman, Darshan S Chandrashekar, Chakravarthi Balabhadrapatruni, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
International Journal of Physiology, Pathophysiology and Pharmacology|May 18, 2016
The mitochondria-targeted antioxidant MitoQ attenuates liver fibrosis in miceHasibur Rehman, Qinlong Liu, Yasodha Krishnasamy, et al.
Molecular Neurodegeneration|June 23, 2025
The PKCι-β-arrestin2 axis disrupts SORLA retrograde trafficking, driving its degradation and amyloid pathology in Alzheimer's diseaseHasibur Rehman, Shun Yan, Shalini Saggu, et al.
JCI Insight|July 19, 2022
ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitorsHasibur Rehman, Darshan S Chandrashekar, Chakravarthi Balabhadrapatruni, et al.
Pageof 5